Furthermore, our prognostic analysis demonstrated that BLCA patients with elevated FAM171B protein levels exhibited significantly lower overall survival (OS) (Fig. 1E), progression-free survival (PFS) (Fig. 1F), and disease-specific survival (DSS) rates (Fig. 1G). The gene discussed is FAM171B; the disease is bladder transitional cell carcinoma.